Category Archives: drug development

Neurobehavioral health company Blackthorn pulls in $76 million from GV to treat mental disorders

There are numerous challenges to finding effective treatments for mental disorders. However, Blackthorn Therapeutics, a neurobehavioral health company using machine learning to create personalized medicine for mental health, is betting its technological approach to finding drugs that work will put it ahead of the competition. Lucky for them, GV and other biotech investors have shown they agree by adding another $76 million in Series B financing to the coffers. Today, Blackthorn announced the close of its $76 million series B round from GV, Scripps Research, Johnson & […]

Read more

Groupon cofounder Eric Lefkofsky just raised another $200 million for his newest company, Tempus

When serial entrepreneur Eric Lefkofsky grows a company, he puts the pedal to the metal. When in 2011 his last company, the Chicago-based coupons site Groupon, raised $950 million from investors, it was the largest amount raised by a start-up, ever. It was just over three years old at the time, and it went public later that same year. Lefkofsky seems to be stealing a page from the same playbook for his newest company Tempus. The Chicago-based genomic testing and data analysis company was founded a little […]

Read more